Viewing nowNeo Empag 10 mg (Empagliflozin)
Empagliflozin 10mg
Tablet · Prescription medication
Nokshim Co., Ltd.

MFDS item code 202105546 · Approved 2021.07.26 · Insurance code 643606160
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is used as an adjunct treatment alongside dietary and exercise therapy to assist adult patients with type 2 diabetes in managing their blood sugar levels. It can be used alone or in conjunction with other hypoglycemic agents. It is particularly important for patients with cardiovascular disease to consult a specialist regarding the risk of cardiovascular events during treatment if their blood sugar levels are not adequately controlled. This medication is effective in improving blood sugar control in type 2 diabetes.
The recommended dose of this medicine is 10 mg once daily, both as monotherapy and as add-on combination therapy with other glucose-lowering agents, such as insulin. If 10 mg of this medicine is well tolerated but additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this medicine is used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, Section 3. Adverse Reactions). This medicine may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. Do not take a double dose on the same day. Special populations •Patients with renal impairment No dose adjustment is necessary in patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) below 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this medicine well but have a persistently reduced glomerular filtration rate below 60ml/min/1.73m2 [or CrCl < 60 ml/min], the dose of this medicine should be adjusted to or maintained at 10 mg once daily. This medicine should be discontinued if the glomerular filtration rate decreases to below 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. Do not use this medicine in patients with end-stage renal disease (ESRD) or those on dialysis, as efficacy is not expected. •Patients with hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment because it has not been studied in this population. •Elderly patients No dose adjustment is necessary based on age. Renal function and the risk of volume depletion should be considered in patients 75 years of age or older. Initiation of treatment with this medicine is not recommended in patients 85 years of age or older because clinical experience is limited (see Precautions for Use, Section 4. General Precautions).
This medication should not be used by individuals who have allergic reactions to the main component or other ingredients of this medication. This medication should not be administered to patients with type 1 diabetes or diabetic ketoacidosis. This medication should not be used in patients with severely impaired kidney function, specifically those with a glomerular filtration rate of less than 30 mL/min/1.73m² or patients receiving dialysis due to end-stage renal disease. Additionally, this medication contains lactose, therefore it should not be administered to patients with genetic disorders such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption. Caution is advised when using this medication in patients with mildly impaired kidney function, and it is not recommended to start treatment in patients with a glomerular filtration rate of less than 60 mL/min/1.73m². If kidney function deteriorates to below 45 mL/min/1.73m², the use of this medication should be discontinued. In patients with heart failure, especially those with mild to moderate cases, caution is required; it is not recommended for patients with severe heart failure. When used in conjunction with medications that can cause hypoglycemia, such as insulin or sulfonylureas, dose adjustments may be necessary due to the risk of hypoglycemia. While taking this medication, side effects such as hypoglycemia, genital infections, increased urination, urinary tract infections, decreased fluid volume, increased serum creatinine, etc., may occur, so caution is advised. Severe metabolic acidosis, known as ketoacidosis, can occur rarely, so if symptoms such as vomiting, abdominal pain, or shortness of breath arise, immediate consultation with healthcare professionals is necessary. Moreover, elderly patients or those at risk of fluid loss should be cautious of dehydration and hypotension, and discontinuation of this medication may be necessary as needed. This medication can increase the risk of urinary tract infections and genital fungal infections, so it is essential to promptly treat any signs of infection. Caution is required when driving or operating machinery due to the risk of hypoglycemia. Women who are pregnant or planning to become pregnant should avoid using this medication, and those who are breastfeeding are advised to discontinue breastfeeding during treatment. The safety and efficacy of this medication in pediatric patients under 18 years of age have not been confirmed. Although no specific toxic symptoms have been reported in cases of overdose, appropriate treatment is required based on the patient’s condition. Finally, this medication should be stored out of reach of children and should not be transferred to other containers for safety.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent exposure to air or moisture. It is important to maintain storage temperatures between 1 and 30 degrees Celsius.
Pale yellow round film-coated tablets
PTP - 30 tablets/PTP [(10 tablets/PTP X 3)], PTP - 10 tablets/PTP [(10 tablets/PTP X 1)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowEmpagliflozin 10mg
Tablet · Prescription medication
Nokshim Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Donggu Bio Pharmaceutical Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Dong Gu Bio Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Korea Prime Pharmaceuticals Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Korea Prime Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Kips Biopharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.